𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I–II study

✍ Scribed by Bernard R. Greenberg; Ralph D. Reynolds; Carolyn B. Charron; Kathleen M. Squillace; Lawrence S. Lessin; Delvyn C. Case Jr.; Richard A. Gams

Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
375 KB
Volume
71
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of idarubicin in the tr
A phase II study of idarubicin in the treatment of measurable gastric cancer
✍ Ronald Maccormick; Geralynn Hirsch; Sunil Gupta; Pat Shannon; Lorne Rotstein 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

Idarubicin is one of the new anthracycline analogues. It has a higher therapeutic index than either doxorubicin or daunorubicin in a variety of murine leukemias and solid tumors. The authors performed a multicenter Phase II trial of idarubicin in patients with advanced gastric cancer. Seventeen pati

A Phase II study of oral idarubicin as a
A Phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time
✍ Hans-Peter Schmid; Rudolf Maibach; Juerg Bernhard; Franz Hering; Silvia Hanselma 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 1 views

## Background: Treatment of hormone-refractory prostate carcinoma with chemotherapy is purely palliative, and reported response rates have been low. at the time this study was conducted, there was an urgent need for a trial using potentially efficacious drugs, with quality of life (ql), and serial

Phase II study of daily oral etoposide i
Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors
✍ Needle, Michael N.; Molloy, Patricia T.; Geyer, J. Russell; Herman-Liu, Alisa; B 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Pre-clinical data and adult experience suggests that topoisomerase targeted anti-cancer agents may be highly schedule dependent, and efficacy may improve with prolonged exposure. To investigate this hypothesis, 28 children with recurrent brain and solid tumors were enrolled in a phase II study of or